Unimed, Searle deal

UMED received U.S. marketing and distribution rights to Searle’s Maxaquin (lomefloxacin) fluoroquinolone

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE